Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials

By afschroeder • May 21, 2026

Thaçi D, Puig L, Motegi SI, Papp K, Stein Gold L, Kircik L, Sofen H, Fernández-Peñas P, Herranz P, Vestergaard C, Huang YH, Dossenbach M, Elmaraghy H, Gallo G, Rueda MJ, Casillas M, Yang C, Agell H, Falqués M, Nosbaum A. Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials. Acta Derm Venereol. 2026 May 21;106. doi: 10.2340/actadv.v106.adv-2025-0160. PMID: 42163822.

Tags: Dermatology, Olive View DoM, Publications

Reply to Botto et al’s “Applicant interview metrics and preference signaling in dermatology: A serial cross-sectional study”

Fleshner L, Chan R, Klufas T, Grant-Kels JM, Zhou AE. Reply to Botto et al's "Applicant interview metrics and preference signaling in dermatology: A serial[...]

Identification of a spatially organized TREM2-associated permissive macrophage niche in human pulmonary tuberculosis alveolar pneumonia

Teles RMB, Benabdessalem C, Perrie J, Wei C, West J, de Andrade Silva BJ, Andrade PR, Mansky LA, Divaka P, Fischbacher L, Lam K, Ma[...]

The State of Mohs Micrographic Surgery in 2025-2026: Current Challenges, Pressures, and the Path Forward

Zhou AE, Gronbeck C, Kim JJ, Yu S, Feng H, Klufas DM. The State of Mohs Micrographic Surgery in 2025-2026: Current Challenges, Pressures, and the[...]